Neurodegenerative pathways in Parkinson's disease: therapeutic strategies

Curr Drug Targets CNS Neurol Disord. 2005 Aug;4(4):405-19. doi: 10.2174/1568007054546072.

Abstract

Parkinson's disease (PD), considered one of the major neurological disorders, is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by the presence of intraneuronal cytoplasmic inclusions called Lewy bodies. The causes for degeneration of PD neurons remain unclear, however, recent findings contributed to clarify this issue. This review will discuss the current understanding of the mechanisms underlying Parkinson's disease pathogenesis, focusing on the current and potential therapeutic strategies for human treatment.

Publication types

  • Review

MeSH terms

  • Animals
  • Antioxidants / therapeutic use
  • Dopamine / metabolism
  • Dopamine Agents / therapeutic use*
  • Estrogens / therapeutic use
  • Humans
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Models, Neurological
  • Nerve Degeneration / metabolism*
  • Nerve Degeneration / pathology
  • Nerve Degeneration / therapy
  • Neurons / metabolism*
  • Neurons / pathology
  • Neurosurgical Procedures
  • Oxidative Stress / physiology
  • Parkinson Disease / metabolism*
  • Parkinson Disease / physiopathology
  • Parkinson Disease / therapy
  • Proteasome Endopeptidase Complex / metabolism

Substances

  • Antioxidants
  • Dopamine Agents
  • Estrogens
  • Proteasome Endopeptidase Complex
  • Dopamine